Evaluation of solitary thyroid nodules

Annals of Surgical Oncology

Volumn 7, Issue 5, 2000, Pages 376-398

  Evans, Douglas B ^a  

^a NONE

Author keywords

[No Author keywords available]

Indexed keywords

RADIOACTIVE IODINE; THYROID HORMONE;

ASPIRATION BIOPSY; BEAM THERAPY; CANCER ADJUVANT THERAPY; CANCER HORMONE THERAPY; REVIEW; SUBTOTAL THYROIDECTOMY; THYROID CANCER; THYROID MEDULLARY CARCINOMA; THYROID NODULE; THYROID PARAFOLLICULAR CELL; THYROIDECTOMY;

EID: 0343527391     PISSN: 10689265     EISSN: None     Source Type: Journal    
DOI: None     Document Type: Review

References (153)

1. Vander JB, Gaston EA, Dawber TR. The significance of nontoxic thyroid nodules: Final report of a 15-year study of the incidence of thyroid malignancy. Ann Intern Med 1968;69:537-40.
2. Simeone JF, Daniels GH, Mueller PR, et al. High resolution real time sonography of the thyroid. Radiology 1982;145:431-5.
3. Landis SH, Murray T, Bolden S, Wingo PA. Cancer statistics. 1998. CA Cancer J Clin 1998;48:6-29.
4. Leight GG. Nodular goiter and benign and malignant neoplasms of the thyroid. In: Sabiston DC, Lyerly HK, eds. Textbook of Surgery: The Biological Basis of Modern Surgical Practice. Philadelphia: WB Saunders; 1997;626-37.
5. Hermus AR, Huysmans DA, Van Herle AJ, et al. Treatment of benign nodular thyroid disease. N Engl J Med 1998;338:1438-47.
6. Gharib H, Mazzaferri EL. Thyroxine suppressive therapy in patients with nodular thyroid disease. Ann Intern Med 1998;128: 386-94.
7. Mazzaferri EL, Young RL. Papillary thyroid carcinoma: A 10 year follow-up report of the impact of therapy in 576 patients. Am J Med 1981;70:511-8.
8. Radecki PD, Arger PH, Arenson RL, et al. Thyroid imaging: Comparison of high resolution real time ultrasound and computed tomography. Radiology 1984;153:145-7.
9. Ashcraft MW, Van Herle AJ. Management of thyroid nodules: I. History and physical examination, blood tests, x-ray tests, and ultrasonography. Head Neck Surg 1981;3:216-30.
10. Ashcraft MW, Van Herle AJ. Management of thyroid nodules: II. Scanning techniques, thyroid suppressive therapy, and fine-needle aspiration. Head Neck Surg 1981;3:297-322.
11. Gharib H. Fine-needle aspiration biopsy of thyroid nodules: Advantages, limitations, and effect. Mayo Clin Proc 1994;69:44-9.
12. Gharib H, Goellner JR, Johnson DA. Fine-needle aspiration cytology of the thyroid. A 12-year experience with 11,000 biopsies. Clin Lab Med 1991;13:699-709.
13. Lowhagen T, Granberg PO, Lundell G, et al. Aspiration biopsy cytology in nodules of the thyroid gland suspected to be malignant. Surg Clin North Am 1979;59:3-18.
14. Grant CS, Hat ID, Gough IR, at al. Long term follow-up of patients with benign thyroid fine-needle aspiration cytologic diagnoses. Surgery 1989;106:980-5.
15. Tyler DS, Winchester DJ, Caraway NP, Hickey R, Evans DB. Indeterminate fine-needle aspiration biopsy of the thyroid: Identification of subgroups at high risk for invasive carcinoma. Surgery 1994;116:1054-60.
16. Kini SK. Guides to clinical aspiration biopsy. In: Thyroid. New York: Igaku-Shoin, 1987;121-87.
17. Boyd LA, Earnhardt RC, Dunn JT, Frierson HF, Hanks JB. Preoperative evaluation and predictive value of fine-needle aspiration and frozen section thyroid nodules. J Am Coll Surg 1998; 187:494-502.
18. Dwarakanathan AA, Ryan WG, Staren ED, et al. Fine-needle aspiration biopsy of the thyroid. Diagnostic accuracy when performing a moderate number of such procedures. Arch Intern Med 1989;149:2007-9.
19. Keller MP, Crabbe MM, Norwood S. Accuracy and significance of fine-needle aspiration and frozen section in determining extent of thyroid resection. Surgery 1987;101:632-5.
20. Silverman JF, West RL, Larkin EW, et al. The role of fine-needle aspiration biopsy in the rapid diagnosis and management of thyroid neoplasm. Cancer 1986;57:1164-7.
21. Kini SR, Miller JM, Hamburger JI, Smith-Purslow MJ. Cytopathology of follicular lesions of the thyroid gland. Diagn Cytopathol 1985;1:123-32.
22. Kung IT. Distinction between colloid nodules and follicular neoplasms of the thyroid. Further observation of cell blocks. Acta Cytol 1990;34:345-51.
23. Kung IT, Yuen RW. Fine-needle aspiration of the thyroid: Distinction between colloid nodules and follicular neoplasms using cell blocks and 21 gauge needles. Acta Cytol 1989;33:53-60.
24. Luck JB, Mumaw VR, Fable WJ. Fine-needle aspiration biopsy of the thyroid. Differential diagnosis by the videoplan image system. Acta Cytol 1982;26:793-6.
25. Montironi R, Braccischi A, Scarpelli M, et al. Well differentiated follicular neoplasms of the thyroid: Reproducibility and validity of a decision tree classification based upon nucleolar and karyometric features. Cytopathology 1992;3:209-22.
26. Montironi R, Alberti R, Sisti S, et al. Discrimination between follicular adenoma and follicular carcinoma of the thyroid: Preoperative validity of cytometry on aspiration smears. Appl Pathol 1989;7:367-74.
27. Cusick EL, Ewen SW, Krukowski ZH, Matheson NA. DNA aneuploidy in follicular thyroid neoplasm. Br J Surg 1991;78: 94-6.
28. Grant CS, Hay ID, Ryan JJ, et al. Diagnostic and prognostic utility of flow cytometric DNA measurements in follicular thyroid tumors. World J Surg 1990;14:283-90.
29. Greenebaum E, Koss LG, Elequin F, Silver CE. The diagnostic value of flow cytometric DNA measurements in follicular tumors of the thyroid gland. Cancer 1985;56:2011-8.
30. Hamburger JI. Consistency of sequential needle biopsy findings for thyroid nodules. Management implications. Arch Intern Med 1987;147:97-9.
31. Dwarakanathan AA, Staren ED, D'Amore MJ, et al. Importance of repeat fine-needle biopsy in the management of thyroid nodules. Am J Surg 1993;166:350-2.
32. Ridgway EC. Clinical review 30: Clinician's evaluation of a solitary thyroid nodule. J Clin Endocrinol Metab 1992;74:231-5.
33. Harness JK, Thompson NW, McLeod MK, Eckhauser FE, Lloyd RV. Follicular carcinoma of the thyroid gland: Trends and treatment. Surgery 1984;96:972-80.
34. McHenry CR, Rosen IB, Walfish PG, Bedard Y. Influence of fine-needle aspiration biopsy and frozen section examination on the management of thyroid cancer. Am J Surg 1993;166:353-6.
35. Hamburger JI, Hamburger SW. Declining role of frozen section in surgical planning for thyroid nodules. Surgery 1985;98:307-12.
36. Cady B, Rossi R. An expanded view of risk-group definition in differentiated thyroid carcinoma. Surgery 1988;104:947-53.
37. Hay ID, Bergstralh EJ, Goellner JR, Ebersold JR, Grant CS. Predicting outcome in papillary thyroid carcinoma: Development of a reliable prognostic scoring system in a cohort of 1779 patients surgically treated at one institution during 1940-1989. Surgery 1993;114:1050-8.
38. Jossart GH, Clark OH. Well-differentiated thyroid cancer. Curr Prob Surg 1994;31:935-1011.
39. Hay ID, Grant CS, Taylor WF, McConahey WM. Ipsilateral lobectomy versus bilateral lobar resection in papillary thyroid carcinoma: A retrospective analysis of surgical outcome using a novel prognostic scoring system. Surgery 1987;102:1088-95.
40. Cady B, Rossi R, Silverman M, Wool M. Further evidence of the validity of risk-group definition in differentiated thyroid gland. Surgery 1985;98:1171-78.
41. Shah JP, Loree TR, Dharker D, Strong EW, Begg C, Vlamis V. Prognostic factors in differentiated carcinoma of the thyroid gland. Am J Surg 1992;164:658-61.
42. Shaha A, Loree TR, Shah JR. Intermediate-risk group for differentiated carcinoma of the thyroid. Surgery 1994;116:1036-41.
43. Byar DP, Green SB, Dor P, et al. A prognostic index for thyroid carcinoma. A study of the E.O.R.T.C. Thyroid Cancer Cooperative Group. Eur J Cancer 1979;15:1033-41.
44. Cunningham MP, Duda RB, Recant W, et al. Survival discrimination for differentiated thyroid cancer. Am J Surg 1990;160: 344-47.
45. Shaha AR, Loree TR, Shah JP. Prognostic factors and risk group analysis in follicular carcinoma of the thyroid. Surgery 1995;118: 1131-38.
46. Shaha AR, Shah JP, Loree TR. Risk group stratification and prognostic factors in papillary carcinoma of the thyroid. Ann Surg Oncol 1996;3:534-8.
47. Andersen PE, Kinsella J, Loree TR, Shaha AR, Shah JP. Differentiated carcinoma of the thyroid with extrathyroidal extension. Am J Surg 1995;170:467-70.
48. Rosai J, Carcangiu ML, DeLellis RA. Tumors of the thyroid gland. In: Atlas of Tumor Pathology, 3rd Series, Washington, DC: Armed Forces Institute of Pathology; 1992:343.
49. Mazzaferri EL, Jhiang SM. Long-term impact of initial surgical and medical therapy on papillary and follicular thyroid cancer. Am J Med 1994;97:418-28.
50. Mazzaferri E, Young RL, Oertel JE, et al. Papillary thyroid carcinoma: The impact of therapy in 576 patients. Medicine 1977;56:171-96.
51. DeGroot LJ, Kaplan EL, McCortick M, et al. Natural history, treatment, and course of papillary thyroid carcinoma. J Clin Endocrinol Metab 1990;71:414-24.
52. 131 therapy in the management of thyroid cancer: A prospective study. Cancer 1977;40:195-202.
53. Samaan NA, Schultz PN, Hickey RC, et al. The results of various modalities of carcinoma: a retrospective review of 1599 patients. J Clin Endocrinol Metab 1992;75:714-20.
54. 131I therapy for well-differentiated thyroid cancer-a quantitative radiation dosimetric approach: Outcome and validation in 85 patients. J Nucl Med 1992;33:1132-36.
55. Ozata M, Suzuki S, Miyamoto T, et al. Serum thyroglobulin in the follow-up of patients with treated differentiated thyroid cancer. J Clin Endocrinol Metab 1994;79:98-105.
56. Coburn M, Teates D, Wanebo HJ. Recurrent thyroid cancer: Role of surgery versus radioactive iodine. Ann Surg 1994;219:593-5.
57. Ladenson PW, Braverman LE, Mazzaferri EL, et al. Comparison of recombinant human thyrotropin administration to thyroid hormone withdrawal for radioactive iodine scanning in patients with thyroid carcinoma. N Engl J Med 1997;337:888-96.
58. 131I scanning with recombinant human thyrotropin versus thyroid hormone withdrawal in a patient with metastatic thyroid carcinoma and hypopituitarism. J Clin Endocrinol Metab 1996;81:1724-5.
59. Massin JP, Savoie JC, Gamier H, et al. Pulmonary metastases in differentiated thyroid carcinoma: Study of 58 cases with implications for the primary tumor treatment. Cancer 1984;53:982-92.
60. Schlumberger M, Arcangioli O, Piekarski JD, et al. Detection and treatment of lung metastases of differentiation thyroid carcinoma in patients with normal chest x-rays. J Nucl Med 1988;29:1790-4.
61. Clark OH. Total thyroidectomy: The treatment of choice for patients with differentiated thyroid cancer. Ann Surg 1982;196: 361-70.
62. DeGroot LJ, Kaplan EL. Second operations for "completion" of thyroidectomy in treatment of differentiated thyroid cancer. Surgery 1991;110:936-40.
63. Grant CS, Hay ID, Gough IR, et al. Local recurrence in papillary thyroid carcinoma: Is extent of surgical resection important? Surgery 1988;104:954-62.
64. McConahey WM, Hay ID, Woolner LB, et al. Papillary thyroid cancer treated at the Mayo Clinic 1946 through 1970: Initial manifestations, pathologic findings, therapy, and outcome. Mayo Clin Proc 1986;61:978-96.
65. Clark OH. Papillary thyroid carcinoma: Rationale for total thyroidectomy. In: Clark OH, Duh QY, eds. Textbook of Endocrine Surgery. Philadelphia: WB Saunders: 1997:90-3.
66. Cady B, Sedgwick CE, Meissner WA, et al. Risk factor analysis in differentiated thyroid cancer. Cancer 1979;43:810-20.
67. Nemec J, Zamrazil V, Pohunkova D, et al. Radioiodine treatment of pulmonary metastases of differentiated thyroid cancer: Results and prognostic factors. Nuklearmedizin 1979;18:86-90.
68. LiVolsi VA. Papillary lesions of the thyroid. In Zorab, R, ed. Surgical Pathology of the Thyroid. Philadelphia: WB Saunders; 1990;136-72.
69. Carcangiu ML, Zampi G, Pupi A, et al. Papillary carcinoma of the thyroid. A clinicopathologic study of 241 cases treated at the University of Florence, Italy. Cancer 1985;55:805-28.
70. Attie JN, Moskowitz GW, Margouleff D, et al. Feasibility of total thyroidectomy in the treatment of thyroid carcinoma: Postoperative radioactive iodine evaluation of 140 cases. Am J Surg 1979; 138:555-60.
71. Thompson NW. Total thyroidectomy in the treatment of thyroid carcinoma. In: Thompson NE, Vinik AL, eds. Endocrine Surgery Update. New York: Grune & Stratton; 1983;71-84.
72. Sosa JA, Bowman HM, Tielsch, MD, et al. The importance of surgeon experience for clinical and economic outcomes from thyroidectomy. Ann Surg 1998;228:320-30.
73. Udelsman R, Lakatos E, Ladenson P. Optimal surgery for papillary thyroid carcinoma. World J Surg 1996;20:88-93.
74. Singer PA, Cooper DS, Daniels GH, et al. Treatment guidelines for patients with thyroid nodules and well-differentiated thyroid cancer. Arch Intern Med 1996;156:2165-72.
75. Schlumberger M, Tubiana M, De Vathaire F, et al. Long-term results of treatment of 283 patients with lung and bone metastases from differentiated thyroid carcinoma. J Clin Endocrinol Metab 1986;63:960-67.
76. 131I uptake post-thyroidectomy for thyroid cancer. J Clin Endocrinol Metab 1980;50: 734-9.
77. 131I scintiscans and thyroglobulin testing. Thyroid 1996;6:69-73.
78. Maxon HRd, Smith HS. Radioiodine-131 in the diagnosis and treatment of metastatic well differentiated thyroid cancer. Endocrinol Metab Clin North Am 1990;19:685-718.
79. Waxman A, Ramanna L, Chapman N, et al. The significance of I-131 scan dose in patients with thyroid cancer: Determination of ablation: Concise communication. J Nucl Med 1981;22:861-65.
80. Nemec J, Rohling S, Zamrazil V, Pohunkova D. Comparison of the distribution of diagnostic and thyroablative I-131 in the evaluation of differentiated thyroid cancers. J Nucl Med 1979;20: 92-7.
81. Park HM. Stunned thyroid after high-dose I-131 imaging. Clin Nucl Med 1992;17:501-2.
82. Sherman SI, Tielens ET, Sostre S, et al. Clinical utility of posttreatment radioiodine scans in the management of patients with thyroid carcinoma. J Clin Endocrinol Metab 1994;78:629-34.
83. Simpson WJ, Panzarella T, Carruthers JS, et al. Papillary and follicular thyroid cancer: Impact of treatment in 1578 patients. Int J Radiat Oncol Biol Phys 1988;14:1063-75.
84. Wong JB, Kaplan MM, Meyer KB, Pauker SG. Ablative radioactive iodine therapy for apparently localized thyroid carcinoma: A decision analytic perspective. Endocrinol Metab Clin North Am 1990;19:741-60.
85. Taylor T, Specker B, Robbins J, et al. Outcome after treatment of high-risk papillary and non-Hurthle cell follicular thyroid carcinoma. Ann Intern Med 1998;129:622-27.
86. Beierwaltes WH, Rabbani R, Dmuchowski C, et al. An analysis of "ablation of thyroid remnants" with I-131 in 511 patients from 1947-1984: Experience at University of Michigan. J Nucl Med 1984;25:1287-93.
87. Crile G, Jr. The endocrine dependency of certain thyroid cancers and the danger that hypothyroidism may stimulate their growth. Cancer 1957;10:1119-37.
88. Cooper DS, Specker B, Ho M, et al. Thyrotropin suppression and disease progression in patients with differentiated thyroid cancer: Results from the National Thyroid Cancer Treatment Cooperative Registry. Thyroid 1998;8:737-44.
89. Pujol P, Daures J-P, Nsakala N, et al. Degree of thyrotropin suppression as a prognostic determinant in differentiated thyroid cancer. J Clin Endocrinol Metab 1996;81:4318-23.
90. Stall GM, Harris S, Sokoll LJ, Dawson-Hughes B. Accelerated bone loss in hypothyroid patients overtreated with L-thyroxine. Ann Intern Med 1990;113:265-9.
91. Diamond T, Nery L, Hales I. A therapeutic dilemma: Suppressive doses of thyroxine significantly reduce bone mineral measurements in both premenopausal and postmenopausal women with thyroid carcinoma. J Clin Endocrinol Metab 1991;72:1184-8.
92. Sawin CT, Geller A, Wolf PA, et al. Low serum thyrotropin concentrations as a risk factor for atrial fibrillation in older persons. N Engl J Med 1994;331:1249-52.
93. Fazio S, Biondi B, Carella C, et al. Diastolic dysfunction in patients on thyroid-stimulating hormone suppressive therapy with levothyroxine: Beneficial effect of b-blockade. J Clin Endocrinol Metab 1995;80:2222-6.
94. Biondi B, Fazio S, Cuocolo A, et al. Impaired cardiac reserve and exercise capacity in patients receiving long-term thyrotropin suppressive therapy with levothyroxine. J Clin Endocrinol Metab 1996;81:4224-8.
95. Biondi B, Fazio S, Carella C, et al. Cardiac effects of long term thyrotropin-suppressive therapy with levothyroxine. J Clin Endocrinol Metab 1993;77:334-8.
96. Shapiro LE, Sievert R, Ong L, et al. Minimal cardiac effects in asymptomatic athyreotic patients chronically treated with thyrotropin-suppressive doses of L-thyroxine. J Clin Endocrinol Metab 1997;82:2592-5.
97. Sherman SI, Chiu AC, Kopelen H, Zoghbi W. Minimal resting cardiac effects of TSH-suppressive doses of L-thyroxine. Thyroid 1997;7:S58.
98. Grigsby PW, Baglan K, Siegel BA. Surveillance of patients to detect recurrent thyroid carcinoma. Cancer 1999;85:945-51.
99. Spencer CA, Wang C-C. Thyroglobulin measurement: Techniques, clinical benefits, and pitfalls. Endocrinol Metab Clin North Am 1995;24:841-63.
100. Pacini F, Lari R, Mazzeo S, et al. Diagnostic value of a single serum thyroglobulin determination on and off thyroid suppressive therapy in the follow-up of patients with differentiated thyroid cancer. Clin Endocrinol 1985;23:405-11.
101. LoGerfo P, Colacchio T, Colacchio D, Feind C. Effects of TSH stimulation on serum thyroglobulin in metastatic thyroid cancer. J Surg Oncot 1980;14:195-200.
102. Muller-Gaertner HW, Schneider C. Clinical evaluation of tumor characteristics predisposing serum thyroglobulin to be undetectable in patients with differentiated thyroid cancer. Cancer 1988; 61:976-81.
103. Mariotti S, Barbesino G, Caturegli P, et al. Assay of thyroglobulin in serum with thyroglobulin autoantibodies: An unobtainable goal? J Clin Endocrinol Metab 1995;80:468-72.
104. Spencer CA, Takeuchi M, Kazarosyan M, et al. Serum thyroglobulin autoantibodies: Prevalence, influence on serum thyroglobulin measurement, and prognostic significance in patients with differentiated thyroid carcinoma. J Clin Endocrinol Metab 1998;83: 1121-27.
105. Ringel MD, Ladenson PW, Levine MA. Molecular diagnosis of residual and recurrent thyroid cancer by amplification of thyroglobulin messenger ribonucleic acid in peripheral blood. J Clin Endocrinol Metab 1998;83:4435-42.
106. Antonelli A, Miccoli P, Fedeghini M, et al. Role of neck ultrasound in the follow-up of patients operated on for thyroid cancer. Thyroid 1995;5:25-8.
107. Franceschi M, Kusic Z, Franceschi D, et al. Thyroglobulin determination, neck ultrasonography and iodine-131 whole-body scintigraphy in differentiated thyroid carcinoma. J Nucl Med 1996;37:446-51.
108. Baudin E, Schlumberger M, Lumbroso J, et al. Octreotide scintigraphy in patients with differentiated thyroid carcinoma: Contribution for patients with negative radioiodine scan. J Clin Endocrinol Metab 1996;81:2541-4.
109. Lind P, Gallowitsch HJ, Langsteger W, et al. Technetium-99m-tetrofosmin whole body scintigraphy in the follow-up of differentiated thyroid carcinoma. J Nucl Med 1997;38:348-52.
110. Burman K, Anderson J, Wartofsky L, et al. Management of patients with thyroid carcinoma: Application of thallium-201 scintigraphy and magnetic resonance imaging. J Nucl Med 1990; 31:1958-64.
111. Sherman SI. Adjuvant therapy and long-term management of differentiated thyroid carcinoma. Semin Surg Oncol 1999;16: 30-3.
112. Hurthle K. Beitrage zur kenntnis des Sekretionsvorganges in der schilddruse. Arch F D Ges Physiol 1894;56:1-44.
113. McLeod MK, Thompson NW. Hurthle cell neoplasms of the thyroid. Otolaryngol Clin North Am 1990;23:441-52.
114. Langhans T. Uber die Epithelialan Formen der Malignen Struma. Virchows Arch 1907;189:69.
115. Askanazy M. Pathologisch-Anatomische Beitrage zur Kenntnis des Morbus Basedowii, Insbesondere uder die Dabei Auftretende Muskelerkrankung. Deutsches Arch F Klin Med 1898;61:118.
116. Bondeson L, Bondeson A, Ljungberg O, et al. Oxyphil tumors of the thyroid: Follow-up of 42 surgical cases. Ann Surg 1981;194: 677-80.
117. Johnson, TL, Lloyd RV, Burney RE, et al. Hurthle cell thyroid tumors: An immunohistochemical study. Cancer 1987;59:107-12.
118. Kini SR, Miller JM, Hamburger JI. Cytopathology of Hurthle cell lesions of the thyroid gland by fine-needle aspiration. Acta Cytol 1981;25:647-52.
119. Grant CS. Operative and postoperative management of the patient with follicular and Hurthle cell carcinoma: Do they differ? Surg Clinic NA 1995;75:395-403.
120. Gundry SR, Burney RE, Thompson NW, Lloyd R. Total thyroidectomy for Hurthle cell neoplasms of the thyroid. Arch Surg 1983;118:529-32.
121. Bondeson L, Bondeson A, Ljungberg O. Treatment of Hurthle cell neoplasms of the thyroid. Arch Surg 1983;118:1453.
122. Rosen IB, Luk S, Katz I. Hurthle cell tumor behavior. Dilemma and resolution. Surgery 1985;98:777-83.
123. Samaan NA, Schultz PN, Haynie TP, et al. Pulmonary metastasis of differentiated thyroid carcinoma: Treatment results in 101 patients. J Clin Endocrinol Metab 1985;60:376-80.
124. Carcangiu ML, Bianchi S, Savino D, et al. Follicular Hurthle cell tumors of the thyroid. Cancer 1991;68:1944-53.
125. Gonzalez JL, Wang HH, Ducatman BS. Fine-needle aspiration to Hurthle cell lesions: A cytomorphologic approach to diagnosis. Am J Clin Pathol 1993;100:231-5.
126. Grant CS, Barr D, Goellner JR, et al. Benign Hurthle cell tumors of the thyroid: A diagnosis to be trusted? World J Surg 1988;12: 488-95.
127. Bondeson L, Azavedo E, Bondeson A, et al. Nuclear DNA content and behavior of oxyphil thyroid tumors. Cancer 1986;58: 672-5.
128. Bronner MP, Clevenger CV, Edmonds PR, et al. Flow cytometric analysis of DNA content in Hurthle cell adenomas and carcinomas of the thyroid. Am J Clin Pathol 1988;89:764-9.
129. McLeod MK, Thompson NW, Hudson JL, et al. Flow cytometric measurements of nuclear DNA and ploidy analysis in Hurthle cell neoplasms of the thyroid. Arch Surg 1988;123:849-56.
130. Ryan JJ, Hay ID, Grant CS, et al. Flow cytometric DNA measurements in benign and malignant Hurthle cell tumors of the thyroid. World J Surg 1988;12:482-7.
131. McIvor NP, Freeman JL, Rosen I, et al. Value of fine-needle aspiration in the diagnosis of Hurthle cell neoplasms. Head Neck Surg 1993;15:335-41.
132. El-Naggar AK, Batsakis JG, Luna MA, et al. Hurthle cell tumors of the thyroid. Arch Otolaryngol Head Neck Surg 1988;114: 520-1.
133. Gosain AK, Clark OH, Hurthle cell neoplasms. Malignant potential. Arch Surg 1984;119:515-9.
134. Moley, J. F. Medullary thyroid cancer. Surg Clin North Am 1995;75: 405-20.
135. Mulligan, L., Kwok, J, Healy, C. Germ-line mutations of the RET proto-oncogene in multiple endocrine neoplasia type 2A (MEN 2A). Nature 1993;363:458-60.
136. Donis-Keller H, Dou S, Chi D, et al. Mutations in the RET proto-oncogene are associated with MEN 2A and FMTC. Hum Mol Genet 1993;2:851-6.
137. Wells SA, Chi DD, Toshima K, et al. Predictive DNA testing and prophylactic thyroidectomy in patients at risk for multiple endocrine neoplasia type 2A. Ann of Surg 1994;220:237-50.
138. Moley JF, DeBenedetti M. Patterns of nodal metastases in palpable medullary thyroid carcinoma. Ann Surg 1999;229:880-8.
139. Tung W, Moley JF. Laparoscopic detection of hepatic metastases in patients with residual or recurrent medullary thyroid cancer. Surgery 1995;118:1024-30.
140. Tisell L, Hansson G, Jansson S, Salander H. Reoperation in the treatment of asymptomatic metastasizing medullary thyroid carcinoma. Surgery 1986;99:60-6.
141. Moley, J, Dilley, W, DeBenedetti, M. Improved results of cervical reoperation for medullary thyroid carcinoma. Ann Surg 1997; 225:734-43.
142. Moley, JF, Wells, SA, Dilley, WG, Tisell, L. E. Reoperation for recurrent or persistent medullary thyroid cancer. Surgery 1993; 114:1090-5.
143. Dottorini ME, Assi A, Sironi M, et al. Multivariate analysis of patients with medullary thyroid carcinoma. Cancer 1996;77:1556-65.
144. Fuchshuber PR, Loree TR, Hicks WL, Jr, et al. Medullary carcinoma of the thyroid: prognostic factors and treatment recommendations. Ann Surg Oncol 1998;5:81-6.
145. Girelli MD, Nacamulli D, Pelizzo MR, et al. Medullary thyroid carcinoma: Clinical features and long-term follow-up of seventy-eight patients treated between 1969 and 1986. Thyroid 1998;8: 517-23.
146. Brierley J, Tsang R, Simpson WJ, et al. Medullary thyroid cancer: Analyses of survival and prognostic factors and the role of radiation therapy in local control. Thyroid 1996;6:305-10.
147. Saad MF, Ordonez NG, Rashid RK, et al. Medullary carcinoma of the thyroid. Medicine 1984;63:319-41.
148. Tisell LE, Dilley WG, Wells SA. Progression of postoperative residual medullary thyroid carcinoma as monitored by plasma calcitonin levels. Surgery 1996;119:34-9.
149. Evans DB, Fleming JB, Lee JE, Cote G, Gagel RF. The surgical treatment of medullary thyroid carcinoma. Semin Surg Oncol 1999;16:50-63.
150. Dralle H, Damm I, Scheumann GF, et al. Compartment-oriented microdissection of regional lymph nodes in medullary thyroid carcinoma. Surg Today 1994;24:112-21.
151. Gimm O, Ukkat J, Dralle H. Determinative factors of biochemical cure after primary and reoperative surgery for sporadic medullary thyroid carcinoma. World J Surg 1998;22:562-7.
152. Kallinowski F, Buhr HJ, Meybier H, et al. Medullary carcinoma of the thyroid-therapeutic strategy derived from fifteen years of experience. Surgery 1993;114:491-6.
153. Fleming JB, Lee JE, Bouvet M, et al. Operative strategy for the treatment of medullary thyroid carcinoma. Ann Surg 1999;230: 697-707.